Our research teams leverage advanced facilities, innovative scientific platforms, and deep technical expertise to continuously expand their knowledge, strengthen capabilities, and advance our science. This ongoing investment in research and development has enabled us to build a robust pipeline across multiple therapeutic areas.With a strong focus on innovation and differentiation, our pipeline is designed to generate promising solutions that address evolving healthcare needs and create meaningful value for patients and partners.
| Molecule | Modality | Therapeutic Area | Indication | Phase | Information |
|---|---|---|---|---|---|
|
Bimekizumab (IL-17 A/F): Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes. |
Monoclonal antibody |
Immunology |
Hidradenitis Suppurativa (>9y / 12y-18y) |
1 – 2 – 3 |
Topline results in H1 2027 |
|
Palmoplantar Pustulosis (PPP) |
1 – 2 – 3 |
Topline results in 2028 |
|||
|
Psoriasis (6y-18y) |
1 – 2 – 3 |
Topline results in H2 2027 |
|||
|
Juvenile Idiopathic Arthritis (2y-18y) |
1 – 2 – 3 |
Topline results in 2028 |
|||
|
Rozanolixizumab (FcRn inhibitor): Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies. |
Monoclonal antibody |
Neurology |
Myelin oligodendrocyte glycoprotein (MOG) antibody disease |
1 – 2 – 3 |
Topline results in H2 2027 (event driven) |
|
Ocular myasthenia gravis |
1 – 2 – 3 |
Phase 3 initiated – Topline results in 2029 |
|||
|
Fenfluramine (5-HT and sigma-1 receptors): Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor |
Small molecule |
Neurology |
CDKL5 deficiency disorder |
1 – 2 – 3 – 4 |
Filed |
|
RETT-Syndrome |
1 – 2 – 3 |
Phase 3 initiated – Topline results in 2029 |
|||
|
Dapirolizumab pegol (anti-CD40L antibody): Dapirolizumab pegol is an investigational humanised monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L). Through interactions with its receptor, CD40, CD40L plays an important role in regulating interactions between T cells and other immune cells and thus affects several important functional events thought to be involved in autoimmune disease.
Dapirolizumab pegol is being co-developed with Biogen. |
Monoclonal antibody |
Immunology |
Systemic lupus erythematosus |
1 – 2 – 3 |
Topline results of 2nd phase 3 in 2028 |
|
STACCATO® alprazolam (benzodiazepine): STACCATO® alprazolam is an investigational drug-device combination using STACCATO® delivery technology with alprazolam, a benzodiazepine, that has the potential to be the first rescue treatment to be administered by a patient or caregiver in an out-patient setting to rapidly terminate (within 90 seconds) an ongoing seizure. |
Small molecule |
Neurology |
Stereotypical prolonged seizures |
1 – 2 – 3 |
Topline results in Q4 2026 / H1 2027 (event driven) |
|
Rezanecel (GABA interneuron cell therapy): Rezanecel is an investigational allogenic regenerative GABA interneuron cell therapy, administered in a one-time, minimally invasive delivery procedure designed to integrate into dysregulated neural circuits and restore inhibitory tone |
Cell therapy |
Neurology |
Mesial Temporal Lobe Epilepsy |
1 – 2 – 3 |
Phase 3 to start in H1 2027 |
|
Bepranemab (anti-tau antibody): Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody with specificity for human tau protein. |
Monoclonal antibody |
Neurology |
Alzheimer’s disease |
1 – 2 |
Signal-confirming Phase 2 to start in H1 2027 |
|
Glovadalen (D1 receptor positive allosteric modulators): Glovadalen is an investigational selective dopamine D1 receptor positive allosteric modulator. This orally available, brain-penetrant, small molecule is designed to enhance the potency of dopamine ‘when and where needed’ to activate the dopamine D1 receptor and thereby improve symptom control. It is being studied for the treatment of Parkinson’s disease. |
Small molecule |
Neurology |
Parkinson’s disease |
1 – 2 |
Positive Phase 2a. Next steps under evaluation |
|
Galvokimig (IL-13 & IL-17 A/F): Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked. |
Multi-specific antibody |
Immunology |
Atopic dermatitis |
1 – 2 |
Phase 2b – Topline results (52-week) in 2028 |
|
Non Cystic Fibrosis Bronchiectasis (NCFB) |
Phase 2 initiated in Q3 2026 – Topline results in 2029 |
||||
|
Chronic Obstructive Pulmonary Disease (COPD) |
Phase 2 initiated in Q3 2026 – Topline results in 2029 |
||||
|
Cizutamig (BCMA x CD3 T-cell engager): Cizutamig is an investigational bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing plasma cells and B-cells |
Multi-specific antibody |
Immunology |
Myasthenia gravis & Systemic autoimmune rheumatic disease associated interstitial lung disease |
1 – 2 |
Phase 2 planned to start end 2026 |